Drug Study ResultsPositive results from Drug-Drug Interaction (DDI) study further supports use of NXP900 in combination therapies.
Financial StatusNuvectis ended with $18.5M in cash and no debt, and closed an equity offering receiving net proceeds of $14.4M, providing sufficient capital to fund operations into 2027.
Safety ProfileNo serious or severe adverse events were observed in the NXP900 study, indicating a favorable safety profile for potential combinations.